MOSCOW, June 26 (RAPSI) – The Moscow Regional Commercial Court has dismissed a lawsuit against Russian Nativa company filed by an Irish subsidiary of the U.S. drug corporation Bristol-Myers Squibb International Holdings, which sought to prohibit production of a medicine, the press-service of the defendant has stated.

According to the plaintiff, production of dasatinib drug by the defendant may violate its patent rights.

The court, however, ruled that Nativa did not violate the plaintiff’s exclusive rights and refused to grant the lawsuit.

CEO of Nativa Alexander Malin said that foreign companies persist in their attempts to hinder the activity of Russian production enterprises.